). Gene expression with MAL for SRF binding. We propose that RhoA, MAL, profiles were monitored using Affymetrix microarrays. SRF, and FHL2 constitute an autoregulatory feedback For further analysis, we focused on the subset of 86 mechanism regulating the expression of subsets of SRF genes, which were also activated by SRF-VP16 (see target genes during myogenesis. above). Self-organizing map (SOM) clustering of the selected 86 genes yielded four different clusters, each representing a group of genes sharing a common serum Results induction profile ( Figure 1A ).
Only genes found in clusters b (51 genes) and d (8 genes) displayed a robust Expression Profiling to Identify SRF-Regulated serum induction. The remaining 27 genes in clusters a Genes in ES Cells
and c, although activated by SRF-VP16, were not inDespite increasing evidence for important functions of duced strongly by serum. Genes in cluster d displayed SRF in various biological processes, further insight is the classical induction profile of IEGs and included the hampered by incomplete knowledge of SRF target known SRF-responsive IEGs Egr-1, Egr-2, JunB, Cyrgenes. We used a microarray approach to monitor SRF-61, and ␥-actin ( Figure 1B ). SRF-regulated cytoskeletal dependent gene expression at the whole-genome level.
genes, such as SM22␣, muscle actins and vinculin, disWe took advantage of the Srf Ϫ/Ϫ ES cell system, which played a more transient serum induction profile and allows robust induction of SRF target genes indepenwere primarily found in cluster b. In total, 14 out of dent of signal transduction upon overexpression of the 17 previously known SRF target genes were found in constitutively active SRF fusion protein SRF-VP16. SRFclusters b and d, confirming our initial hypothesis that ⌬M-VP16, a mutant defective in DNA binding, served as the expression of most SRF target genes would be incontrol . To monitor gene expression duced by both SRF-VP16 and serum stimulation. We profiles of cells transfected with SRF-VP16 or SRF-⌬M-infer that clusters b and d are enriched for novel SRF VP16, mRNA from two independent transfections was target genes. Therefore, scoring for independent activahybridized to Affymetrix microarrays (see Supplemental tion by SRF-VP16 and serum represents a stringent filter Table S3 ). This frequency (32.6%) is We next verified SRF-dependent expression for several genes identified in our screen using quantitative RTsignificantly higher (p ϭ 1.023 ϫ 10 Ϫ5 ) than the frequency obtained if one were to pick 86 genes randomly from PCR. We focused on three genes containing a conserved consensus CArG box (tuftelin, Fhl2, and KRTthe mouse genome (1,864 in a total of 13,540 mouse genes, resulting in a frequency of 13.8%). If the analysis 17) and two genes containing CArG-like sequences (CTGF and ET-1). In Srf Ϫ/Ϫ ES cells, SRF-VP16 signifiis restricted to perfect CArG consensus sequences, the difference is more pronounced ( genes identified in our screen. To determine whether SRF binds directly to the identiEighteen previously unrecognized SRF target genes were identified (Supplemental Table S3 Figure 4D ). To explore a potential interac-CRP1 and 2, we investigated a potential direct interac-tion between endogenous SRF and FHL2, we performed of full-length and mutant FHL2 proteins was confirmed by Western blotting (data not shown). We conclude that coimmunoprecipitation assays using rat embryonic heart extracts. We detected FHL2 in anti-SRF immuno-FHL2 antagonizes RhoA-dependent activation of specific SRF target genes. precipitates, indicating that SRF and FHL2 interact in cells of the developing heart ( Figure 4E ). FHL2 and SRF colocalize in the nucleus of rat cardiomyocytes, sug-FHL2 Antagonizes MAL gesting that the FHL2/SRF interaction occurs in the nu-MAL is a potent SRF-dependent activator of both cleus (Supplemental Figure S4) . smooth and cardiac muscle genes. Similar to FHL2, MAL Together, these experiments show that SRF and FHL2 has been shown to accumulate in the nucleus after RhoA directly interact in vitro and form a RhoAV14-dependent activation. We investigated whether FHL2 could intercomplex in vivo.
fere with MAL activation of SRF target genes in response to RhoA in 293T cells. MAL and RhoAV14 synergistically activated the SMA, SM22␣, and ANF promoters. Coex-FHL2 and SRF Bind to the Promoters pression of FHL2 led to a significant reduction in SM22␣ of SM-Specific SRF Target Genes and SMA activation, but did not interfere with activation We used ChIP to determine whether FHL2 and SRF bind of the ANF promoter (Figures 6A-6C) . Similarly, expresto the promoters of SRF target genes in differentiated sion of FHL2 did not affect c-fos or tk80 promoter activi-E14 Srf ϩ/ϩ ES cells (d8). As expected, SRF was bound ties ( Figures 6D and 6E ). This suggests that FHL2 can to the promoters of the SRF target genes Egr-1, Srf, interfere with MAL-mediated activation of a specific SMA, and SM22␣ ( Figure 4F, lanes 3 and 7) . FHL2 specifsubset of RhoA-responsive SRF target genes, including ically bound to the same SM22␣ and SMA promoter the SM-specific genes SM22␣ and SMA. regions recognized by SRF, and FHL2 binding was
In undifferentiated Srf Ϫ/Ϫ ES cells, expression of SRF strongly increased upon RhoA activation (lanes 4 and and MAL led to an efficient induction of SMA and SM22␣ 8). In contrast, FHL2 binding was not detectable at the mRNA levels, which could be further increased by coexEgr-1 and Srf promoters irrespective of RhoA activity. pression of RhoAV14. Simultaneous coexpression of Neither SRF nor FHL2 were able to bind to the CArG FHL2 significantly reduced RhoA/MAL-mediated activabox-deficient ␤-globin promoter. Our results indicate tion ( Figures 6F and 6G ), demonstrating that FHL2 is able that FHL2 is selectively recruited to the promoters of to interfere with RhoA/MAL-stimulated transcription of the SM-specific SRF target genes SMA and SM22␣ in the endogenous SM-specific SRF target genes SMA and response to RhoA signaling.
SM22␣. In contrast, RNAi-mediated knockdown of Fhl2 had no effect on the expression of SM22␣, SMA, and 
